other material
confidence high
sentiment positive
materiality 0.90
Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint in Phase 3 SYMPHONY Trial for Narcolepsy
Axsome Therapeutics, Inc.
- AXS-12 reduced weekly cataplexy attacks by 83% vs 66% for placebo (p=0.018) at Week 5.
- Cataplexy remission achieved by 33% of AXS-12 patients vs 9.5% placebo (p=0.008).
- Excessive daytime sleepiness severity reduced (CGI-S p=0.027) and cognitive function improved (p=0.004).
- Concurrent EDS and cataplexy response in 57% of AXS-12 patients vs 33% placebo (p=0.029).